We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Metabolon Selected for Membership in NCI Research Group
News

Metabolon Selected for Membership in NCI Research Group

Metabolon Selected for Membership in NCI Research Group
News

Metabolon Selected for Membership in NCI Research Group

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Metabolon Selected for Membership in NCI Research Group"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Metabolon, Inc. has announced it has been selected as a member of the National Cancer Institute’s (NCI) Early Detection Research Network (EDRN). 

This is Metabolon’s second project with NCI but first project as a member of the EDRN will be a collaboration with the University of Michigan to discover disease biomarkers for prostate cancer. 

"Membership in the EDRN is a great privilege," said Dr. John Ryals, president and CEO of Metabolon.

"Metabolon will be able to collaborate with other members to discover and develop biomarkers for the early diagnosis of cancers."

Metabolon will share its technology and metabolomics expertise with Dr. Arul Chinnaiyan of the University of Michigan on the prostate cancer project.

"Metabolon is at the forefront in the emerging area of metabolomics, and we are extremely excited about embarking on this collaboration," said Dr. Chinnaiyan. 

"If metabolomic biomarkers can be identified for prostate cancer, Metabolon’s technology platform may have applications in other cancers as well."

Advertisement